Psychiatr. pro Praxi, 2005; 3: 136-139

ANTIEPILEPTIC MEDICATIONS IN THE THERAPY OF PSYCHOSIS OF SCHIZOPHRENIC TYPE

MUDr. Ludvík Nábělek, MUDr. Ján Vongrej
Psychiatrické oddelenie, FNsP FBR, Banská Bystrica

A significant minority of schizophrenic patients fail to respond to standard antipsychotic therapy. An alternative way of enhancing efficacy may be the use of augemntation strategies with other classes of drugs. Anticonvulsants are increasingly being used as adjunctive treatment in both acute and long-term management strategies for psychosis. Valproate is the most commonly prescribed adjunct to manage: mood disturbances as well as impulsivity, hostility and aggression in psychosis. Some reports note a beneficial role of anticonvulsants in the management of treatmentrefractory psychosis.

Keywords: Key words: treatment-refractory schizophrenia, anticonvulsants, carbamazepine, valproate.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nábělek L, Vongrej J. ANTIEPILEPTIC MEDICATIONS IN THE THERAPY OF PSYCHOSIS OF SCHIZOPHRENIC TYPE. Psychiatr. praxi. 2005;9(3):136-139.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Casey DE. Anticonvulsants as adjunctive treatment in psychosis. Přednáška na APA 2001 Armual meeting, New Orleans, 2001.
    2. Casey DE, et al. Effect of divalproex combined with. olanzapine or risperidone in patients with acute exacerbation of schizophrenia. Neurops.ychopharmacology, 2003; 28: 182-192. Go to original source...
    3. Češková E, Kašpárek T. Kdy je polyfarmakoterapie léčbou první nebo druhé volby? I. část. Čes a slov Psychiat, 2003; 99: 134-141.
    4. Češková E, Kašpárek T. Kdy je polyfarmakoterapie léčbou první nebo druhé volby? II. část. Čes a slov Psychiat, 2003; 99: 189-193.
    5. Dose M, et al. Combined treatment of schizophrenic psychosis with haloperidol and valproat. Pharmacopsychiatry, 1998; 31: 122-125. Go to original source... Go to PubMed...
    6. Garpenter WT, et al. Carbamazepine maintenance treatment in outpatient scdzophrenics. Arch Gen Psychiatry, 1991; 48: 69-72. Go to original source... Go to PubMed...
    7. Kahn EM, et al. Gange in haloperidol level due to carbamazepine: a complicating medication for schizophrenia. J Clin Psychopharmacol, 1990; 10: 54-57. Go to original source... Go to PubMed...
    8. Kando JC, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychopharmacol, 1994; 55: 255-257.
    9. Klein E, et al. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry, 1984; 41: 165-170. Go to original source... Go to PubMed...
    10. Moller HJ, et al. Doubleblind evaluation of the antimanic properties of carbamazepine as comedication to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989; 13: 127-136. Go to original source... Go to PubMed...
    11. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiat, 1983; 44: 407-409.
    12. Okuma T, et al. A double blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiat Scand, 1989; 80: 250-259. Go to original source... Go to PubMed...
    13. Schulz SC, et al. Nonresponders to neuroleptics: a distinct subtype. In: Schulz SG, Tamminga CA. (eds): Schizophrenia: Scientific progress. Oxford University Press, 1989: Oxford, 341-350.
    14. Schulz SC, et al. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In: Angrist B, Schulz SC, (eds.). The neuroleptic nonresponsive patient: characterization and treatment. APA, 1990: Washington DS, 109-136.
    15. Schulz SC, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry, 1999; 60: 366-372. Go to original source... Go to PubMed...
    16. Stáhl S. Key issues and urimet needs in schizophrenia. In: Kapur S, Lecrubier Y. (eds.). Dopamine in the pathophysiology anátreatment of schizophrenia. Martin Dunitz, 2003: London, 237-253. Go to original source...
    17. Wassef AA, et al. Randomized, placebo-controlled pilot study of divalproex. sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol, 2000; 20: 357-361. Go to original source... Go to PubMed...
    18. Wassef AA, et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol, 2001; 21: 21-26. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.